Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to specific peptides of C163A or LG3BP, compositions comprising such antibodies and/or fragments, as well as methods of use and devices employing such antibodies and/or fragments.
1. A monoclonal antibody, or antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof comprises:
a heavy chain CDR1 (HC-CDR1) having an amino acid sequence of GFTFSSYA (SEQ ID NO: 1), a heavy chain CDR2 (HC-CDR2) having an amino acid sequence of ISSSGSYT (SEQ ID NO: 2), a heavy chain CDR3 (HC-CDR3) having an amino acid sequence of ARQEGLWSFAY (SEQ ID NO: 3), a light chain CDR1 (LC-CDR1) having an amino acid sequence of QSLLDSDGKTY (SEQ ID NO: 4), a light chain CDR2 (LC-CDR2) having an amino acid sequence of LVS (SEQ ID NO: 5), and a light chain CDR3 (LC-CDR3) having an amino acid sequence of WQGTHFPWT (SEQ ID NO: 6).
2. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof comprises:
a) a V H having an amino acid sequence of SEQ ID NO: 13; and
b) a V L having an amino acid sequence of SEQ ID NO: 14.
3. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, specifically binds to a peptide or protein comprising a sequence of INPASLDK(SEQ ID NO: 44).
4. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, specifically binds to C163A.
5. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is chimeric, humanized, or murine.
6. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is detectably labeled.
7. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, comprises an effector domain.
8. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, comprises an Fc domain.
9. The monoclonal antibody, or antigen-binding fragment thereof, of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is selected from the group consisting of Fv, Fav, F(ab′)2), Fab′, dsFv, scFv, sc(Fv)2, and diabodies fragments.
10. A monoclonal antibody, or antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof comprises:
(1) a HC-CDR1 having an amino acid sequence of GYTFSSYW (SEQ ID NO: 7, a HC-CDR2 having an amino acid sequence of INRSNGRT (SEQ ID NO: 8), a HC-CDR3 having an amino acid sequence of TKWGVTSDY (SEQ ID NO: 9), a LC-CDR1 having an amino acid sequence of SNVNY (SEQ ID NO: 10), a LC-CDR2 having an amino acid sequence of DTS (SEQ ID NO: 11), and a LC-CDR3 having an amino acid sequence of FQGSGYPRT (SEQ ID NO: 12).
11. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody or antigen-binding fragment thereof further comprises:
a) a V H having an amino acid sequence of SEQ ID NO: 15; and
b) a V L having an amino acid sequence of SEQ ID NO: 16.
12. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody, or antigen-binding fragment thereof, specifically binds to a peptide or protein comprising a sequence of VEIFYR (SEQ ID NO: 41).
13. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody, or antigen-binding fragment thereof, specifically binds to LG3BP.
14. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is chimeric, humanized, or murine.
15. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is detectably labeled.
16. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody, or antigen-binding fragment thereof, comprises an effector domain.
17. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody, or antigen-binding fragment thereof, comprises an Fc domain.
18. The monoclonal antibody, or antigen-binding fragment thereof, of claim 10 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is selected from the group consisting of Fv, Fav, F(ab′)2), Fab′, dsFv, scFv, sc(Fv)2, and diabodies fragments.